Standardized Rhodiola Rosea Extract (SHR-5) Improves Cognitive Performance and Fatigue in Burnout Syndrome

Burnout is not just a psychological state of feeling tired; it is a physiological syndrome characterized by chronic hypothalamic-pituitary-adrenal (HPA) axis dysregulation. Under chronic work or emotional pressure, the brain's cortisol feedback loops break down, leaving individuals with a flat cortisol awakening response (CAR), severe morning lethargy, and an inability to maintain cognitive focus.

While traditional medicine prescribed adaptogenic roots for stamina, modern clinical science requires objective, quantifiable measurements of cognitive processing and HPA axis endocrine activity.

To address this, researchers designed a double-blind, randomized, placebo-controlled trial to evaluate how a patented Siberian Rhodiola rosea extract (SHR-5) affects actual salivary cortisol curves and sustained attention parameters in subjects with burnout syndrome.

This research explainer provides a detailed breakdown of the study design, measurement instruments, physiological findings, and clinical implications of this trial.

---

1. Study Design & Participant Criteria

The study was designed as a randomized, double-blind, placebo-controlled clinical trial conducted over a 28-day (4-week) intervention period.

Participant Profiles

The trial enrolled sixty adult volunteers (aged 20 to 55) who met the following strict diagnostic criteria:

• Diagnosed with stress-induced burnout syndrome (according to Swedish national clinical guidelines)
• Showing elevated baseline scores on the Pine Burnout Scale (indicating high exhaustion and cognitive wear)
• No history of psychotic disorders, major clinical depression, or thyroid disease
• No use of conventional antidepressants, stimulants, or other adaptogenic herbs within 3 months prior to enrollment

Targeting a population with clinically diagnosed burnout is vital. Unlike healthy subjects (who maintain stable baseline cortisol), individuals with burnout syndrome have flattened circadian curves and impaired neural feedback loops, providing a clear baseline for evaluating an adaptogen's normalizing, homeostatic properties.

The Intervention

Participants were randomly assigned to one of two groups:

1. The Active Group (30 subjects): Received 576 mg of standardized Rhodiola rosea SHR-5 extract daily, split into two 288 mg doses taken in the morning and early afternoon on an empty stomach.
2. The Control Group (30 subjects): Received an identical placebo capsule.

---

2. Measurement Methodology

To measure both subjective recovery and objective physiological markers, researchers combined psychological scoring with laboratory endocrine assays and cognitive testing:

Salivary Cortisol Response to Waking (CAR)

Rather than a single blood draw, researchers collected saliva samples at waking, and at 15, 30, and 60 minutes post-waking on Day 0 and Day 28. Salivary cortisol is a validated measurement of free, bio-active cortisol (unbound by blood proteins). This series of draws mapped the shape of the cortisol awakening response (CAR) curve.

The Conners' Continuous Performance Test (CPT)

To measure cognitive attention, participants performed the CPT — a computerized task requiring sustained focus and rapid motor response to visual targets. The CPT measures:

• Omission Errors: Failure to respond to targets (indicating lapses in attention).
• Commission Errors: Incorrectly responding to non-targets (indicating impulsivity or processing speed errors).
• Reaction Time: Speed of cognitive processing.

Burnout and Fatigue Scales

Subjective fatigue was evaluated using the Pine Burnout Scale (assessing physical, emotional, and mental exhaustion) and visual analog scales for daytime vitality.

---

3. Primary Outcomes & Findings

By Day 28, the group receiving active Rhodiola rosea SHR-5 extract demonstrated statistically significant improvements in HPA axis regulation, cognitive processing, and overall exhaustion scores compared to the placebo group.

       Salivary Cortisol Waking Curve (Day 28)
┌──────────────────────────────────────────────┐
│Active Group: Normalized CAR (restored curve) │
├──────────────────────────────────────────────┤
│Placebo Group: Flat CAR (sustained burnout)   │
└──────────────────────────────────────────────┘

Key Statistical Results

Normalization of the Cortisol Curve (CAR):

• At baseline, both groups demonstrated a flattened CAR curve, typical of adrenal burnout.
• By Day 28, the active Rhodiola rosea group showed a statistically significant normalization of the cortisol awakening response curve, showing a healthy morning rise and post-waking decline.
• The placebo group showed no change, remaining flat.

Cognitive Performance Improvements (CPT):

• The rhodiola group showed significant reductions in omission errors and faster reaction times on the CPT, indicating improved sustained attention and cognitive processing speed under stress.
• The placebo group demonstrated no significant change in CPT metrics.

Subjective Burnout Reductions:

• Exhaustion scores on the Pine Burnout Scale dropped significantly in the active group, with participants reporting improved morning energy, reduced mental fatigue, and a greater capacity to handle work tasks.

---

4. Understanding the Molecular Mechanism

The metabolic and cognitive outcomes observed in this trial align with the known pharmacological mechanisms of active rhodiola:

MAO Enzyme Inhibition and Dopaminergic Tone

As explained in the Rhodiola rosea profile, active rosavins and salidrosides mildly inhibit monoamine oxidase (MAO) enzymes.

During chronic stress and burnout, MAO enzymes are often over-activated, rapidly breaking down monoamine neurotransmitters. By inhibiting this breakdown, the extract sustains synaptic levels of dopamine and norepinephrine in the prefrontal cortex, enhancing focus, attention, and executive function.

Hsp70 Activation and Mitochondrial Protection

Rhodiola compounds stimulate cellular expression of heat shock protein 70 (Hsp70). Under chronic stress, Hsp70 acts as a molecular chaperone, protecting mitochondrial proteins from denaturing and preserving the integrity of the inner mitochondrial membrane where ATP is recycled.

---

5. Safety, Tolerability, and Side Effects

• Exceptional Safety: No serious adverse events were reported during the 4-week trial.
• Gastrointestinal Tolerance: The extract was well-tolerated, with zero reports of significant stomach upset or digestive changes.
• Sleep Preservation: Because the afternoon dose was taken early in the day (before 2:00 PM), participants reported no insomnia or sleep fragmentation. Taking stimulating adaptogens late in the day can cause sleep disruption.

---

6. Trial Limitations and Future Research Needs

• Duration: The study tracked participants for 28 days. While 4 weeks was sufficient to show initial HPA axis stabilization, longer-term trials (spanning 8 to 12 weeks) are needed to determine if these benefits are sustained or if receptor adaptation occurs.
• Salivary vs. Blood Testing: While salivary testing is the gold standard for free cortisol, measuring ACTH and DHEA levels in the blood would provide a more complete picture of the feedback loop's recovery.
• DHEA Ratios: Future studies should monitor the cortisol-to-DHEA ratio, as DHEA acts as the HPA axis's anabolic counterweight to catabolic cortisol.

This guide is for educational purposes only. Readers should consult qualified healthcare professionals before starting, altering, or combining any supplement routine.